What is the treatment for hydronephrosis in stage 4 prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for hydronephrosis in stage 4 prostate cancer should prioritize relieving the urinary obstruction and addressing the underlying cancer with androgen deprivation therapy (ADT) and novel systemic agents, such as abiraterone or docetaxel, as recommended by recent guidelines 1. The initial management of hydronephrosis involves decompressing the urinary system through placement of a percutaneous nephrostomy tube or ureteral stent to drain the blocked kidney. For immediate relief, a urinary catheter may be placed if the obstruction is at the bladder level.

  • Key considerations in the treatment of stage 4 prostate cancer include:
    • The use of ADT, which is the primary systemic treatment for metastatic prostate cancer
    • The addition of novel systemic agents, such as abiraterone or docetaxel, for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC)
    • The consideration of other treatment options, such as darolutamide or enzalutamide, for patients with mHSPC
  • According to the recent guidelines 1, ADT plus abiraterone or docetaxel is recommended as first-line treatment for fit men with de novo mHSPC, especially in those with multiple bone metastases or visceral metastases.
  • Pain management is also an important aspect of treatment, and may include opioids, NSAIDs, or palliative radiation therapy.
  • Regular monitoring of renal function through blood tests and imaging is essential to assess treatment response and adjust the treatment plan as needed, as recommended by the guidelines 1.

From the Research

Treatment Options for Hydronephrosis in Stage 4 Prostate Cancer

The treatment for hydronephrosis in stage 4 prostate cancer involves relieving the obstruction in the urinary tract. The following options are available:

  • Nephrostomia: This involves placing a catheter directly into the kidney to drain the urine into a bag outside the body 2.
  • Internal urinary diversion: This involves placing a double-J ureteral stent to divert the urine from the kidney into the bladder 2.
  • Percutaneous nephrostomy: This involves creating a hole in the skin to insert a catheter into the kidney to drain the urine 3, 4.

Factors Influencing Treatment Choice

The choice of treatment depends on various factors, including:

  • Patient's overall health: Nephrostomies are preferred for patients in poor health, while double-J stents are preferred for healthier patients 2.
  • Presence of infections: Nephrostomies are preferred for patients with infections 2.
  • Kidney function: Double-J stents are more effective for patients with well-functioning kidneys and bladder 2.

Efficacy and Safety of Treatment Options

Studies have shown that:

  • Nephrostomies and double-J stents are safe and effective in relieving ureteral obstruction 2, 3.
  • Percutaneous nephrostomy can improve renal function and survival in patients with renal failure 3.
  • Double-J stents can last longer than nephrostomies, but may require more frequent replacements 2.

Quality of Life Considerations

Treatment options can impact quality of life, with:

  • Percutaneous nephrostomy associated with a higher risk of complications, such as pyelonephritis and obstruction 4.
  • Double-J stents associated with a higher risk of urinary tract infections and other complications 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.